Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Palmitylethanolamide

Endocannabinoid
 
BML-FA018-0010 10 mg 45.00 USD
 
BML-FA018-0050 50 mg 157.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-300-146

Endogenous cannabinoid. Weak ligand of CB1 (Ki=23.8µM) and CB2 (Ki=13.9µM) receptor. Inhibits fatty acid amide hydrolase (FAAH) (IC50=5.1µM). Immunosuppressant, anti-inflammatory, anti-nociceptive and anti-convulsant in vivo. The exact mode of action has not yet been revealed. It has been suggested that PEA: i) binds to a yet to be discovered cannabinoid receptor similar to CB2; ii) administered in vivo elicits the synthesis of endogenous agonists of CB2; iii) acts as an "entourage" compound by enhancing the activity and/or by influencing the turnover of endogenous agonists of CB2, possibly but not uniquely, by inhibiting their degradation.

Product Specification

Alternative Name:PEA, Palmidrol
 
Formula:C18H37NO2
 
MW:299.5
 
CAS:544-31-0
 
Purity:≥98% (TLC)
 
Appearance:White solid.
 
Solubility:Soluble in DMSO or 100% ethanol.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at 0-4°C. Stock solutions are stable for up to 3 months at -20°C.
 
ALX-300-146
Please mouse over
ALX-300-146

Product Literature References

Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals: G. Re, et al.; Vet. J. 173, 21 (2007), Review, Abstract;
Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems: L. De Petrocellis, et al.; Clin. Pharmacol. 16, 297 (2002), Abstract;
The palmitoylethanolamide family: a new class of anti-inflammatory agents?: D.M. Lambert, et al.; Curr. Med. Chem. 9, 663 (2002), Abstract;
Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide: K.O. Jonsson, et al.; Br. J. Pharmacol. 133, 1263 (2001), Abstract;
Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors: D.M. Lambert, et al.; Biochim. Biophys. Acta 1440, 266 (1999), Abstract;
Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP: H. Cadas, et al.; J. Neurosci. 16, 3934 (1996), Abstract;
N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation: S. Mazzari, et al.; Eur. J. Pharmacol. 300, 227 (1996), Abstract;
The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons: S.D. Skaper, et al.; PNAS 93, 3984 (1996), Abstract;
Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide: L. Facci, et al.; PNAS 92, 3376 (1995), Abstract;
Isolation and structure of a brain constituent that binds to the cannabinoid receptor: W.A. Devane, et al.; Science 258, 1946 (1992), Abstract;

Related Literature

Brochures
Essential Research Tools for Neurodegeneration & Neural Signaling
Essential Research Tools for Neurodegeneration & Neural Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,